ArticleOncotarget2016
Comparative proteomics of exosomes secreted by tumoral Jurkat T cells and normal human T cell blasts unravels a potential tumorigenic role for valosin-containing protein.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 52 citations in OpenAlex.
- Review
- Jurkat T-Cell Antigen-Independent Elimination of PMA-Activated Neuroblastoma Cells Is Triggered by CCL2/CCR2, Depends Upon Lipid Raft LFA1/ICAM1 Immune Synapses, Is Mediated by m-TRAIL and Is Augmented by the TrkAIII Oncoprotein.International journal of molecular sciences · 2026Article
- Quantifying extracellular vesicle heterogeneity: the effect of process conditions on protein cargo for skin therapy.Stem cell research & therapy · 2025Review
- The role of exosome derived miRNAs in inter-cell crosstalk among insulin-related organs in type 2 diabetes mellitus.Journal of physiology and biochemistry · 2024Review
- Primary Cell Culture as a Model System for Evolutionary Molecular Physiology.International journal of molecular sciences · 2024Review
- Exosome derived from tumor-associated macrophages: biogenesis, functions, and therapeutic implications in human cancers.Biomarker research · 2023Review
- Article
- Mechanisms of diabetic foot ulceration: A review.Journal of diabetes · 2023Review
- Plant-Derived Exosome-like Nanoparticles for Biomedical Applications and Regenerative Therapy.Biomedicines · 2023Review
- Proteomic profiling of serum extracellular vesicles identifies diagnostic markers for echinococcosis.PLoS neglected tropical diseases · 2022Article
- The roles of small extracellular vesicles in cancer and immune regulation and translational potential in cancer therapy.Journal of experimental & clinical cancer research : CR · 2022Review
- Release of VAMP5-positive extracellular vesicles by retinal Müller glia in vivo.Journal of extracellular vesicles · 2022Article
- Article
- Microvesicles released from activated CD4European journal of clinical investigation · 2022Article
- Vesicle Induced Receptor Sequestration: Mechanisms behind Extracellular Vesicle-Based Protein Signaling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- ExtracellularFrontiers in bioengineering and biotechnology · 2022Review
- Exosome microRNAs in Metabolic Syndrome as Tools for the Early Monitoring of Diabetes and Possible Therapeutic Options.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Valosin-Containing Protein (VCP)/p97: A Prognostic Biomarker and Therapeutic Target in Cancer.International journal of molecular sciences · 2021Review
- Emerging roles of exosomal miRNAs in diabetes mellitus.Clinical and translational medicine · 2021Review
- Extracellular Vesicles and Their Role in the Spatial and Temporal Expansion of Tumor-Immune Interactions.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have previously characterized that FasL and Apo2L/TRAIL are stored in their bioactive form inside human T cell blasts in intraluminal vesicles present in multivesicular bodies. These vesicles are rapidly released to the supernatant in the form of exosomes upon re-activation of T cells. In this study we have compared for the first time proteomics of exosomes produced by normal human T cell blasts with those produced by tumoral Jurkat cells, with the objective of identify proteins associated with tumoral exosomes that could have a previously unrecognized role in malignancy. We have identified 359 and 418 proteins in exosomes from T cell blasts and Jurkat cells, respectively. Interestingly, only 145 (around a 40%) are common. The major proteins in both cases are actin and tubulin isoforms and the common interaction nodes correspond to these cytoskeleton and related proteins, as well as to ribosomal and mRNA granule proteins. We detected 14 membrane proteins that were especially enriched in exosomes from Jurkat cells as compared with T cell blasts. The most abundant of these proteins was valosin-containing protein (VCP), a membrane ATPase involved in ER homeostasis and ubiquitination. In this work, we also show that leukemic cells are more sensitive to cell death induced by the VCP inhibitor DBeQ than normal T cells. Furthermore, VCP inhibition prevents functional exosome secretion only in Jurkat cells, but not in T cell blasts. These results suggest VCP targeting as a new selective pathway to exploit in cancer treatment to prevent tumoral exosome secretion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.